在胶质母细胞瘤中打 NK 细胞治疗牌时，白细胞介素 21 是无法击败的。
When playing the NK cell therapy card in glioblastoma, you can't beat interleukin-21.
发表日期：2024 Aug 12
作者：
Nicholas D Huntington
来源：
CANCER CELL
摘要：
胶质母细胞瘤是最常见的脑癌，5年生存率低于10%。这种严峻的预后凸显了对新治疗方法的迫切需要。在本期《Cancer Cell》中，Shanley 等人1 报告了一种创新的工程策略，可增强 NK 细胞对胶质母细胞瘤的免疫力。Crown 版权所有 © 2024。由 Elsevier Inc. 出版。保留所有权利。
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.